What is Artbio's official website?

Artbio's website is http://www.artbio.com

What is Artbio's industry?

Artbio's industry is Biotechnology Research

Who are Artbio's top competitors?

Artbio's top competitors are , , , , , ,

Artbio company information, Employees & Contact Information

Explore related pages

Artbio email format Artbio management contacts

Related company profiles:

ARTBIO is a clinical-stage radiopharmaceutical biotechnology company focused on developing a new class of alpha radioligand therapies (ART). Our unique patient-centric approach is underpinned by a deep understanding of cancer biology and the infrastructure needed to effectively design, manufacture, and distribute our therapies.

Employees: 68
Address: Cambridge, Massachusetts, Us
Industry: Biotechnology Research
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)
Website: http://www.artbio.com
HQ: Cambridge, Massachusetts
Competitors: Nvelop Therapeutics, Delphia Therapeutics, Tessera Therapeutics, Rapport Therapeutics, Myrobalan Therapeutics, Fable Therapeutics, KalVista Pharmaceuticals, Inc., Nuvalent, Inc., Arena BioWorks, Dyno Therapeutics.

Artbio Questions

News

ARTBIO Announces $132 Million Series B Financing to Advance Pipeline of Alpha Radioligand Therapies and Expand Manufacturing and Supply Chain Infrastructure - PR Newswire

ARTBIO Announces $132 Million Series B Financing to Advance Pipeline of Alpha Radioligand Therapies and Expand Manufacturing and Supply Chain Infrastructure PR Newswire

FDA greenlights phase 1 trial of alpha radioligand therapy in mCRPC - Urology Times

FDA greenlights phase 1 trial of alpha radioligand therapy in mCRPC Urology Times

ARTBIO Announces FDA Clearance of IND Application for Lead Alpha Radioligand Therapy AB001 - PR Newswire

ARTBIO Announces FDA Clearance of IND Application for Lead Alpha Radioligand Therapy AB001 PR Newswire

Radiopharma startup Artbio secures $132M to fund testing of Pluvicto rival - BioPharma Dive

Radiopharma startup Artbio secures $132M to fund testing of Pluvicto rival BioPharma Dive

From CAR-T to RLT: Enhancing Precision Oncology with ARTBIO’s Radioligands - Inside Precision Medicine

From CAR-T to RLT: Enhancing Precision Oncology with ARTBIO’s Radioligands Inside Precision Medicine

Radiopharma-focused Artbio paints path to clinic with $132M series B - Fierce Biotech

Radiopharma-focused Artbio paints path to clinic with $132M series B Fierce Biotech

ARTBIO Appoints Four New Board Members, Co-Founder Transitions to Technical Advisory Board Role - PR Newswire

ARTBIO Appoints Four New Board Members, Co-Founder Transitions to Technical Advisory Board Role PR Newswire

ARTBIO raises $132M to fuel alpha radiotherapy push with Pb212 - FirstWord Pharma

ARTBIO raises $132M to fuel alpha radiotherapy push with Pb212 FirstWord Pharma

Artbio attracts $132M as its alpha radioligand program moves into the clinic - Endpoints News

Artbio attracts $132M as its alpha radioligand program moves into the clinic Endpoints News

ARTBio raises $132 million for radiopharmaceuticals - statnews.com

ARTBio raises $132 million for radiopharmaceuticals statnews.com

Artbio takes in $132 million for mid-stage prostate cancer candidate - The Pharma Letter

Artbio takes in $132 million for mid-stage prostate cancer candidate The Pharma Letter

FogPharma and ARTBIO Announce Collaboration to Co-Develop Multiple Helicon™-Enabled Alpha-Particle Radioligand Therapies for the Treatment of Cancer - Business Wire

FogPharma and ARTBIO Announce Collaboration to Co-Develop Multiple Helicon™-Enabled Alpha-Particle Radioligand Therapies for the Treatment of Cancer Business Wire

Radiopharma biotech Artbio raises $132M for cancer therapies - Axios

Radiopharma biotech Artbio raises $132M for cancer therapies Axios

Artbio and 3B Pharmaceuticals to advance α-radioligand therapy for solid tumors - BioWorld MedTech

Artbio and 3B Pharmaceuticals to advance α-radioligand therapy for solid tumors BioWorld MedTech

ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid Tumors - PR Newswire

ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid Tumors PR Newswire

ARTBIO inks exclusive deal with 3BP to grow radioligand pipeline - The Pharma Letter

ARTBIO inks exclusive deal with 3BP to grow radioligand pipeline The Pharma Letter

SpectronRx and ARTBIO Join Forces to Develop and Manufacture Clinical Supply of Novel Alpha Radioligand Therapy AB001 for Indiana and Surrounding States - Business Wire

SpectronRx and ARTBIO Join Forces to Develop and Manufacture Clinical Supply of Novel Alpha Radioligand Therapy AB001 for Indiana and Surrounding States Business Wire

ARTBIO Raises Oversubscribed and Upsized $90 Million Series A Financing to Progress Pipeline and Isotope Technology Development for New Class of Alpha Radioligand Therapies - PR Newswire

ARTBIO Raises Oversubscribed and Upsized $90 Million Series A Financing to Progress Pipeline and Isotope Technology Development for New Class of Alpha Radioligand Therapies PR Newswire

ARTBIO Launches to Develop New Class of Alpha Radioligand Therapies Designed to Maximize Therapeutic Potential - PR Newswire

ARTBIO Launches to Develop New Class of Alpha Radioligand Therapies Designed to Maximize Therapeutic Potential PR Newswire

Oncoinvent Announces Agreement with ARTBIO to Collaborate on Radiopharma Laboratory Facilities - Business Wire

Oncoinvent Announces Agreement with ARTBIO to Collaborate on Radiopharma Laboratory Facilities Business Wire

J&J’s Margaret Yu named Artbio CMO - The Pharma Letter

J&J’s Margaret Yu named Artbio CMO The Pharma Letter

ARTBIO and PharmaLogic Announce Supply Agreement for Lead-212 based Therapeutic Candidate AB001 for New York and Surrounding States - PR Newswire

ARTBIO and PharmaLogic Announce Supply Agreement for Lead-212 based Therapeutic Candidate AB001 for New York and Surrounding States PR Newswire

Investors pour $90M onto ARTBIO's palette less than 6 months after launching - Fierce Biotech

Investors pour $90M onto ARTBIO's palette less than 6 months after launching Fierce Biotech

CDMO Nucleus RadioPharma links up with ARTBIO to help produce prostate cancer candidate for clinical trials - Fierce Pharma

CDMO Nucleus RadioPharma links up with ARTBIO to help produce prostate cancer candidate for clinical trials Fierce Pharma

Artbio launches for alpha-emitting radiopharmaceuticals to treat cancer - Chemical & Engineering News

Artbio launches for alpha-emitting radiopharmaceuticals to treat cancer Chemical & Engineering News

ARTBIO Raises $132M in Series B Financing - FinSMEs

ARTBIO Raises $132M in Series B Financing FinSMEs

Companies like Artbio

Top Artbio Employees

Nikki Hadas

Chief Legal Officer At Artbio

Greater Boston, United States

View
Emanuele Ostuni

n/a

Reinach, Basel-Country, Switzerland, Switzerland

View

3
gmail.com, nanoterra.com, sandoz.com
Philip Palmén

n/a

Helsinki, Uusimaa, Finland, Finland

View

2
gmail.com, gmail.com
Mark Davis

n/a

Madison, Wisconsin, United States, United States

View

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles

Get direct phone numbers & mobile contacts

Access company data & employee information

Works directly on LinkedIn - no copy/paste needed

Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Learn More

How It Works

Get a Free Account

Search the #1 Contact Database

Get contact details of over 750M+ profiles across 60M companies – all with industry-leading accuracy. Sales Navigator and Recruiter users, try out our Email Finder Extension.

Use our AI-Powered Email Finder

Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.

Have a look at Aeroleads Data

Browse our Data

Company Search

a b c d e f g h i j k l m n o p q r s t u v w x y z

Profile Search

a b c d e f g h i j k l m n o p q r s t u v w x y z

List Search

a b c d e f g h i j k l m n o p q r s t u v w x y z

Artbio company information, Employees & Contact Information

Explore related pages

Company Details

Artbio Questions

What is Artbio's official website?

What is Artbio's LinkedIn profile?

How many employees are working in Artbio right now?

What is Artbio's industry?

What are Artbio's top competitors?

What are Artbio's categories?

News

ARTBIO Announces $132 Million Series B Financing to Advance Pipeline of Alpha Radioligand Therapies and Expand Manufacturing and Supply Chain Infrastructure - PR Newswire

FDA greenlights phase 1 trial of alpha radioligand therapy in mCRPC - Urology Times

ARTBIO Announces FDA Clearance of IND Application for Lead Alpha Radioligand Therapy AB001 - PR Newswire

Radiopharma startup Artbio secures $132M to fund testing of Pluvicto rival - BioPharma Dive

From CAR-T to RLT: Enhancing Precision Oncology with ARTBIO’s Radioligands - Inside Precision Medicine

Radiopharma-focused Artbio paints path to clinic with $132M series B - Fierce Biotech

ARTBIO Appoints Four New Board Members, Co-Founder Transitions to Technical Advisory Board Role - PR Newswire

ARTBIO raises $132M to fuel alpha radiotherapy push with Pb212 - FirstWord Pharma

Artbio attracts $132M as its alpha radioligand program moves into the clinic - Endpoints News

ARTBio raises $132 million for radiopharmaceuticals - statnews.com

Artbio takes in $132 million for mid-stage prostate cancer candidate - The Pharma Letter

FogPharma and ARTBIO Announce Collaboration to Co-Develop Multiple Helicon™-Enabled Alpha-Particle Radioligand Therapies for the Treatment of Cancer - Business Wire

Radiopharma biotech Artbio raises $132M for cancer therapies - Axios

Artbio and 3B Pharmaceuticals to advance α-radioligand therapy for solid tumors - BioWorld MedTech

ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid Tumors - PR Newswire

ARTBIO inks exclusive deal with 3BP to grow radioligand pipeline - The Pharma Letter

SpectronRx and ARTBIO Join Forces to Develop and Manufacture Clinical Supply of Novel Alpha Radioligand Therapy AB001 for Indiana and Surrounding States - Business Wire

ARTBIO Raises Oversubscribed and Upsized $90 Million Series A Financing to Progress Pipeline and Isotope Technology Development for New Class of Alpha Radioligand Therapies - PR Newswire

ARTBIO Launches to Develop New Class of Alpha Radioligand Therapies Designed to Maximize Therapeutic Potential - PR Newswire

Oncoinvent Announces Agreement with ARTBIO to Collaborate on Radiopharma Laboratory Facilities - Business Wire

J&J’s Margaret Yu named Artbio CMO - The Pharma Letter

ARTBIO and PharmaLogic Announce Supply Agreement for Lead-212 based Therapeutic Candidate AB001 for New York and Surrounding States - PR Newswire

Investors pour $90M onto ARTBIO's palette less than 6 months after launching - Fierce Biotech

CDMO Nucleus RadioPharma links up with ARTBIO to help produce prostate cancer candidate for clinical trials - Fierce Pharma

Artbio launches for alpha-emitting radiopharmaceuticals to treat cancer - Chemical & Engineering News

ARTBIO Raises $132M in Series B Financing - FinSMEs

Companies like Artbio

Rapport Therapeutics

Delphia Therapeutics

Arena Bioworks

Nvelop Therapeutics

Kalvista Pharmaceuti...

Nuvalent, Inc.

Dyno Therapeutics

Tessera Therapeutics

Fable Therapeutics

Myrobalan Therapeutics

Top Artbio Employees

Nikki Hadas

Chief Legal Officer At Artbio

Emanuele Ostuni

n/a

Philip Palmén

n/a

Mark Davis

n/a

Free Chrome Extension

Aero Online

Select data to include:

How It Works

Get a Free Account

Search the #1 Contact Database

Use our AI-Powered Email Finder

Have a look at Aeroleads Data